Adverum Biotechnologies, Inc. lost $6.62 per diluted share in fiscal year 2024. Over the trailing 12 months, Q4 FY2024 through Q3 FY2025, the same line adds up to a loss of $8.60 per diluted share. The table below carries 13 fiscal years, from 2012 to 2024, and the quarters Adverum Biotechnologies, Inc. has filed alongside them.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Adverum Biotechnologies, Inc. lost $6.62 per diluted share in fiscal year 2024.
Adverum Biotechnologies, Inc. (ADVM) reported a loss of $8.60 per diluted share over the trailing 12 months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings.
Across the 13 fiscal years this page covers, Adverum Biotechnologies, Inc. (ADVM) diluted earnings per share went from -$0.50 in fiscal year 2012 to -$6.62 in fiscal year 2024.
Adverum Biotechnologies, Inc. (ADVM) reported -$2.03 in diluted earnings per share in Q3 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Adverum Biotechnologies, Inc. (ADVM) reported on that line in every period on record.
